Literature DB >> 15951834

Therapeutic targeting of CCR1 attenuates established chronic fungal asthma in mice.

Kristin J Carpenter1, Jillian L Ewing, Jane M Schuh, Traci L Ness, Steven L Kunkel, Monica Aparici, Montserrat Miralpeix, Cory M Hogaboam.   

Abstract

CC chemokine receptor 1 (CCR1) represents a promising target in chronic airway inflammation and remodeling due to fungus-associated allergic asthma. The present study addressed the therapeutic effect of a nonpeptide CCR1 antagonist, BX-471, in a model of chronic fungal asthma induced by Aspergillus fumigatus conidia. BX-471 treatment of isolated macrophages inhibited CCL22 and TNF-alpha and promoted IL-10 release. BX-471 also increased toll like receptor-9 (TLR9) and decreased TLR2 and TLR6 expression in these cells. When administered daily by intraperitoneal injection, from days 15 to 30 after the initiation of chronic fungal asthma, BX-471 (3, 10, or 30 mg kg(-1)) dose-dependently reduced airway inflammation, hyper-responsiveness, and remodeling at day 30 after conidia challenge. The maximal therapeutic effect was observed at the 10 mg kg(-1) dose. In summary, the therapeutic administration of BX-471 significantly attenuated experimental fungal asthma via its effects on both innate and adaptive immune processes.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15951834      PMCID： PMC1576221          DOI： 10.1038/sj.bjp.0706243

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  45 in total

1.  CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model.

Authors:  R Horuk; S Shurey; H P Ng; K May; J G Bauman; I Islam; A Ghannam; B Buckman; G P Wei; W Xu; M Liang; M Rosser; L Dunning; J Hesselgesser; R M Snider; M M Morrissey; H D Perez; C Green
Journal:  Immunol Lett       Date:  2001-04-02       Impact factor: 3.685

2.  Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor.

Authors:  M Liang; M Rosser; H P Ng; K May; J G Bauman; I Islam; A Ghannam; P J Kretschmer; H Pu; L Dunning; R M Snider; M M Morrissey; J Hesselgesser; H D Perez; R Horuk
Journal:  Eur J Pharmacol       Date:  2000-02-11       Impact factor: 4.432

3.  Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.

Authors:  M Liang; C Mallari; M Rosser; H P Ng; K May; S Monahan; J G Bauman; I Islam; A Ghannam; B Buckman; K Shaw; G P Wei; W Xu; Z Zhao; E Ho; J Shen; H Oanh; B Subramanyam; R Vergona; D Taub; L Dunning; S Harvey; R M Snider; J Hesselgesser; M M Morrissey; H D Perez
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

4.  A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.

Authors:  I Sabroe; M J Peck; B J Van Keulen; A Jorritsma; G Simmons; P R Clapham; T J Williams; J E Pease
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

5.  Airway remodeling is absent in CCR1-/- mice during chronic fungal allergic airway disease.

Authors:  K Blease; B Mehrad; T J Standiford; N W Lukacs; S L Kunkel; S W Chensue; B Lu; C J Gerard; C M Hogaboam
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

6.  CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis.

Authors:  B Mehrad; R M Strieter; T A Moore; W C Tsai; S A Lira; T J Standiford
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

7.  Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis during allergic airway disease induced by Aspergillus fumigatus.

Authors:  C M Hogaboam; K Blease; B Mehrad; M L Steinhauser; T J Standiford; S L Kunkel; N W Lukacs
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

8.  Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression.

Authors:  N Zimmermann; S P Hogan; A Mishra; E B Brandt; T R Bodette; S M Pope; F D Finkelman; M E Rothenberg
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

9.  Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma.

Authors:  Vanessa Redecke; Hans Häcker; Sandip K Datta; Agnes Fermin; Paula M Pitha; David H Broide; Eyal Raz
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

10.  Antifungal and airway remodeling roles for murine monocyte chemoattractant protein-1/CCL2 during pulmonary exposure to Asperigillus fumigatus conidia.

Authors:  K Blease; B Mehrad; N W Lukacs; S L Kunkel; T J Standiford; C M Hogaboam
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422
View more
  10 in total

Review 1.  Infectious disease, the innate immune response, and fibrosis.

Authors:  Alessia Meneghin; Cory M Hogaboam
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

2.  Gene expression profiling and network analysis of peripheral blood monocytes in a chronic model of allergic asthma.

Authors:  Glenn P Dorsam; Scott A Hoselton; Ashley R Sandy; Amali E Samarasinghe; Emilie E Vomhof-Dekrey; Sheri T Dorsam; Jane M Schuh
Journal:  Microbiol Immunol       Date:  2010-09       Impact factor: 1.955

3.  Therapeutic Effect of C-C Chemokine Receptor Type 1 (CCR1) Antagonist BX471 on Allergic Rhinitis.

Authors:  Suoyi Feng; Longzhu Ju; Ziqi Shao; Mark Grzanna; Lu Jia; Ming Liu
Journal:  J Inflamm Res       Date:  2020-07-21

Review 4.  CCR1 antagonists.

Authors:  Jie-Fei Cheng; Rick Jack
Journal:  Mol Divers       Date:  2008-06-17       Impact factor: 2.943

5.  Toll-like receptor 9 modulates immune responses to Aspergillus fumigatus conidia in immunodeficient and allergic mice.

Authors:  Hemanth Ramaprakash; Toshihiro Ito; Theodore J Standiford; Steven L Kunkel; Cory M Hogaboam
Journal:  Infect Immun       Date:  2008-10-20       Impact factor: 3.441

6.  Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis.

Authors:  Chuan-Hui Kuo; Andrea M Collins; Douglas R Boettner; YanFen Yang; Santa J Ono
Journal:  J Immunol       Date:  2016-12-12       Impact factor: 5.422

Review 7.  The multiple faces of CCL13 in immunity and inflammation.

Authors:  E Mendez-Enriquez; E A García-Zepeda
Journal:  Inflammopharmacology       Date:  2013-07-12       Impact factor: 4.473

8.  Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.

Authors:  M Amat; C F Benjamim; L M Williams; N Prats; E Terricabras; J Beleta; S L Kunkel; N Godessart
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 9.  Experimental advances in understanding allergic airway inflammation.

Authors:  Christine M Deppong; Jonathan M Green
Journal:  Front Biosci (Schol Ed)       Date:  2013-01-01

10.  Fungal biomarker discovery by integration of classifiers.

Authors:  João Pedro Saraiva; Marcus Oswald; Antje Biering; Daniela Röll; Cora Assmann; Tilman Klassert; Markus Blaess; Kristin Czakai; Ralf Claus; Jürgen Löffler; Hortense Slevogt; Rainer König
Journal:  BMC Genomics       Date:  2017-08-10       Impact factor: 3.969
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.